Home  >  R & D  >  details

PHN033 (Diabetic Nephropathy treatment)

Diabetic nephropathy is a disease with a high incident rate among patients with type 1 and 2 diabetes, and is the major cause of mortality. The pathogenesis of diabetic nephropathy is initially characterized by microalbuminuria, followed by a gradual decline in glomerular function. New evidence has suggested that changes in the glomerular capillary wall and glomerular mesangium in patients with diabetic nephropathy involve pathological and biochemical changes to corresponding glycoproteins. The elevated levels of glucose tend to accelerate the formation of advanced glycation end products (AGEs), which play a key role in the pathogenesis of diabetic complications. Inhibiting the formation of AGEs is likely to become a significant part of treatment for diabetic nephropathy in the future, and can be utilized synergistically alongside conventional methods to prevent kidney damage in patients with diabetes. Due to the increased number of patients suffering from diabetic nephropathy with special treatment requirements that cannot be satisfied by existing methods, the development of new drugs and treatments are required.

PhytoHealth PHN033 is a single-ingredient botanical agent that can facilitate the removal of the AGEs that cause vascular complications in patients with diabetes. It is expected that the product can be used to prevent and treat diabetic nephropathy.

Evidence has revealed that PHN033 can drive nonenzymatic glycosylation and oxidation of lipids and proteins, and can facilitate the removal of AGES in patients with diabetes, a substance that can cause vascular complications.

Currently, Phase II trials have been completed in Taipei Veterans General Hospital, Tri-Service General Hospital, and Taichung Veterans General Hospital; and the technology used in developing PhytoHealth PHN014 has received patent approval from the United States, European Union, Australia, South Korea, mainland China, Japan, Canada, and Taiwan.

Notable achievements


Agreed by US FDA for the PHN033 Phase II clinical trial in 2009


Getting the grants of Technology Development Program for the Ministry of Economic Affairs in 2010


Was awarded the 2011 National Innovation Award


Patented for PHN033 in US, European Union , Australia, South Korea, Canada ,China, Japan and Taiwan.